Status:
TERMINATED
Autoimmune Gastrointestinal Dysmotility: Symptoms, Pathogenesis and Treatment
Lead Sponsor:
Johns Hopkins University
Conditions:
Dysmotility Syndrome
Autoimmunity
Eligibility:
All Genders
15+ years
Brief Summary
Autoimmune gastrointestinal dysmotility syndromes are poorly understood, and often difficult to treat because the underlying pathogenesis is unclear. Refractory symptoms result in an impaired quality ...
Eligibility Criteria
Inclusion
- Males and females, Aged\>15
- Evidence of enteric dysmotility with documented abnormality on objective testing which may include high resolution esophageal manometry, gastric emptying scintigraphy, SmartPill Wireless Motility Capsule, Sitz marker studies, antroduodenal manometry or anorectal manometry.
- English proficiency and literacy sufficient to sign consent form and fill out questionnaires.
- Previous Mayo paraneoplastic panel testing.
- Referring gastroenterologist has recommended intravenous immunoglobulin (IVIg) therapy.
Exclusion
- Non-autoimmune causes of enteric dysmotility (diabetes, adrenal insufficiency, Parkinson's, thyroid, electrolytes, drugs, malignancy).
- Pregnancy as documented in EPIC with serum or urine Human chorionic gonadotropin (hCG) testing
- If participants believe that they are pregnant, they will need to notify a study physician who will order a serum or urine hCG test for pregnancy within EPIC and remove them from the study if the test results come back positive.
- Previous treatment with IVIg.
Key Trial Info
Start Date :
April 22 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 29 2022
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT04859829
Start Date
April 22 2021
End Date
September 29 2022
Last Update
March 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States, 21224